Enable Accessibility Enable Accessibility

Director/PDMR Share Dealings

February 22, 2012

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the following dealings by Persons Discharging Managerial Responsibility (“PDMRs”) in Shire plc ordinary shares of 5p (“Shares”).

Release of Performance Share Awards (“PSA Awards”)

In accordance with the rules of the Portfolio Share Plan (“PSP”), the following Shares were released on February 20, 2012 in connection with PSA Awards granted in 2009 under Part B of the PSP.  The Company was notified on February 21, 2012 that sufficient Shares were sold on February 20, 2012 to satisfy the personal tax liabilities of each PDMR.

  No of Shares released No of Shares sold Average sale price
Angus Russell1 225,582 77,719 £22.564711
Graham Hetherington1 76,318 40,179 £22.538221
Tatjana May 30,527 16,078 £22.538221

1 The PSA Awards granted in 2009 to Angus Russell and Graham Hetherington were subject to performance criteria measured over the performance period 2009 to 2011.  Based on the performance criteria, 100% of the PSA Awards vested. 

Exercise of Stock Appreciation Right Awards (“SAR Awards”)

The Company was notified on February 21, 2012 and on February 22, 2012 of the exercise of the following SAR Awards which were granted under Part A of the PSP.

  No of Shares exercised Exercise price No of Shares received No of Shares sold Average sale price
Angus Russell1 108,721 £8.13 69,953 24,234 £22.557733
Graham Hetherington2 100,000 £8.83 61,135 61,135 £22.571881
Tatjana May3 40,000 £8.83 24,161 24,161 £22.30140

1 The SAR Award granted in 2008 to Mr Russell was subject to performance criteria measured over the performance period 2008 to 2010.  Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on February 20, 2012. Mr Russell sold sufficient Shares to satisfy his personal tax liabilities.

2 The SAR Award granted in 2009 to Mr Hetherington was subject to performance criteria measured over the performance period 2009 to 2011.  Based on the performance criteria, 100% of the SAR Award vested. The SAR Award was exercised on February 20, 2012.  Mr Hetherington sold all his Shares, part of which were to satisfy his personal tax liabilities.

3 Ms May exercised her SAR Award on February 22, 2012 and sold all the resulting Shares, part of which were to satisfy her personal tax liabilities.

Sale of Shares

The Company was notified on February 21, 2012 of the sale by Angus Russell, on February 20, 2012, of 131,330 Shares at an average sale price of £22.564.

In addition, the Company was notified on February 21, 2012 of the sale by Graham Hetherington, on the same day, of 20,000 Shares at an average sale price of £22.300615.

Resulting Interests

After the above transactions, Angus Russell and Graham Hetherington hold the following interests.

  Type of security No of Shares/ADSs SAR Awards/Options PSA Awards Restricted Shares/ADSs
Angus Russell ADSs1 - 168,742 121,292 11,415
  Shares 193,582 295,580 - 37,814
Graham Hetherington Shares 34,004 217,687 159,633 28,080

1 One ADS is equal to three Shares.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

 

For further information please contact:

Investor Relations Eric Rojas (erojas@shire.com) +1 781 482 0999
  Sarah Elton-Farr (seltonfarr@shire.com) +44 1256 894157

 

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.